The UNM Department of Dermatology is actively involved in clinical trials, which allow our patients to have access to investigational medications for a number of skin disorders. We also conduct significant research specific to dermatology and health care disparities, and all of our faculty are measured by their excellence in scholarly activities.
Here are some areas of study for our Department:
Celldex Study for exploring the safety, clinical effect, pharmacodynamics, and pharmacokinetics of CDX-0159 (barzolvolimab) in patients with Prurigo Nodularis.
https://clinicaltrials.gov/ct2/show/NCT04944862
Lichen Planus Study for evaluation of the safety and efficacy of ixekizumab in lichen planus and lichen planopilaris clinical response by Total Body Surface (TBS) determination, Investigator Global Assessment (IGA) Score, Lichen Planopilaris Activity Index (LPPAI), and Frontal Fibrosing Alopecia Severity Score (FFASS).
https://clinicaltrials.gov/ct2/show/NCT05030415
LITE Study for comparing the effectiveness, safety (tolerability), and duration of treatment response at 12 weeks of home versus office-based narrowband ultraviolet B phototherapy for the treatment of psoriasis. Physician Global Assessment (PGA) and Dermatology Life Quality Index (DLQI) will be used to assess effectiveness, safety (tolerability), and duration of treatment response. This is a three year pragmatic, randomized, active comparator effectiveness study.
https://clinicaltrials.gov/ct2/show/NCT03726489
ARQ 151-315 Study for assessing the safety and efficacy of ARQ-151 cream vs vehicle applied once a day for 4 weeks by subjects with atopic dermatitis (eczema).
https://clinicaltrials.gov/ct2/show/NCT04845620
Allegro global Phase 2b/3 study for evaluate the safety and effectiveness of an investigational study drug (called PF-06651600) in adults and adolescents (12 years and older) who have 50% or greater scalp hair loss. The study is placebo-controlled, meaning that some patients entering the study will not receive active study drug but will receive tablets with no active ingredients (a placebo). This is a dose-ranging study, investigating 5 different dosing regimens. It will be double-blinded, meaning that the sponsor, the study doctors, the staff, and the patients will not know whether a patient is on active study drug (or the dose) or placebo.
https://clinicaltrials.gov/ct2/show/NCT03732807
Some of our clinical trials are conducted in the UNM Clinical and Translational Science Center. For more information regarding our clinical trials, please contact our Unit Administrator at hsc-dermatology@salud.unm.edu.
Deparment Mailing Address & Physical Address
Department of Dermatology 1 University of New Mexico MSC07 4240 Albuquerque, NM 87131-0001 505-272-6000 505-272-6003 fax |
1021 Medical Arts Ave NE Albuquerque, NM 87131 |